We encourage dialogue and interaction amongst all participants and we welcome the presence of sponsors to highlight new technologies, services and solutions within the relevant areas. We have many sponsoring opportunities to suit all budgets, but we can also tailor specific packages to suit your needs. Some examples of sponsorship ideas are below, but please feel free to contact us and we’ll be happy to give you more details and talk about your requirements:
- Gold Sponsor
- Silver Sponsor
- Technology Presentation
- Event Documentation
For more information please contact us.
THIS EVENT IS ORGANISED IN PARTNERSHIP WITH:
With a portfolio of more than 3,500 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings.
Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.
Promega holds significant intellectual property rights and licenses in several key areas that form a foundation for its diverse portfolio including:
– Bioluminescence, including engineered luciferases, luciferase reporter vectors and luciferase substrates
– Short tandem repeat (STR) detection for STR-based cell line authentication, human identification, cell and tissue characterisation, and mixed sample detection
– HaloTag® protein labelling and capture technology
Promega supports customers through providing the highest quality products, the best possible customer service, unsurpassed technical support, and many tools and resources for scientists are available online and on several mobile platforms.
Please visit our website: www.promega.com
Takara Bio Europe is a member of the Takara Bio Group, a leading supplier of tools for life scientists worldwide.
Through our brand names TAKARA®, CLONTECH® and CELLARTIS® we develop innovative technologies in the fields of Cell Biology, Molecular Biology, Proteomics and Stem Cell Research. From next-generation sequencing and PCR, to cloning and genomics, we offer high-performance reagents you can count on for all areas of molecular biology.
Key products include SMARTer™ cDNA synthesis kits for Next Generation Sequencing, the innovative In-Fusion® HD Cloning Plus System, high performance PCR/qPCR reagents, Tet-regulated gene expression systems, Living Colors® Fluorescent Proteins, as well as a broad choice of viral vectors/particles and transduction tools. With the recent acquisition of Takara Bio Europe AB (formerly Cellartis), Takara Bio has expanded its portfolio with ready-to-use hiPSC derived hepatocytes and cardiomyocytes, culture media, as well as services such as iPS cell generation, engineering and differentiation. Our best-in-class products are backed by expert technical assistance, because good science needs great support.
QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).
Our top-quality assays and panels enable you to accurately analyze and identify diseases and genetic variations. Our bioinformatics software and curated knowledge bases transform your raw data into relevant, actionable findings. And our automation solutions provide you seamless and cost-effective workflows. Sample to Insight. Further information can be found at www.qiagen.com.
Headquartered in Pleasanton, California, the Roche Sequencing Unit is focused on developing novel sequencing technologies and products to support innovation in clinical research applications. Our goal is to develop assays for sequencing, and refine sequencing techniques to advance sequencing technologies that will deliver truly differentiated clinical value.
Lexogen GmbH is a biotech company based in Vienna, Austria, with unique proprietary RNA-Seq technologies that enable detailed interrogation of the whole transcriptome, mRNA gene expression profiling, small RNA and targeting specific transcripts. Lexogen specializes in the development of novel RNA research tools which range from efficient RNA isolation method (SPLIT), full length cDNA synthesis (TeloPrime), spike-in RNA variant control mixes (SIRVs), RNA-Seq library preparation methods (QuantSeq 3’ mRNA, QuantSeq-Flex, SENSE Total, SENSE mRNA & small RNA), RNA enrichment (Poly(A) RNA selection), rRNA depletion (RiboCop) and data analysis tool (Mix2). Using Lexogen’s QuantSeq 3’ mRNA-Seq library preparation we offer an affordable and reliable full RNA-Seq service from RNA to gene expression profiling data analysis.
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.
We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.
Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.
PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. With our proprietary nucleic acid isolation technology, fully integrated automated library prep, robust sequencing chemistries, sample quality quantitation and visualization tools for analysis of complex sequencing data, we help you deliver top-quality samples for world-class genomics research from start to finish.
Advanced Analytical Technologies Inc. (AATI) develops, manufactures and markets high-throughput, fully-automated nucleic acid and genetic analysis systems. The company’s products have both commercial and research applications and are designed to improve processes within the molecular diagnostics, pharmaceutical, life science, agricultural and biofuels industries. The company’s product portfolio includes instruments for the parallel analysis of biomolecules, DNA, RNA, genomic DNA, double-stranded DNA, gene editing (CRISPR/Cas9), pharmaceutical compounds and proteins using capillary electrophoresis (CE) with fluorescence detection or UV absorbance. The company’s flagship product, the Fragment Analyzer, is recognized as the best-in-class, multi-channel, automated fluorescence-based CE detection system for the simultaneous analysis of the quantity and quality of nucleic acids, including: dsDNA fragments, gDNA, NGS fragments and RNA (total and messenger) and microsatellites (SSR). Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare. The company has facilities in Ames, Iowa, USA and Heidelberg, Germany. We support customers through a global network of distributors and support centers.
Founded in 2011 as a wholly owned subsidiary of Biolegio BV, Nimagen specializes in life sciences applications for R&D and diagnostics with premium quality products for the Molecular Biology sector.
Our product range includes a complete portfolio for DNA Sequencing and Fluorescent Fragment Analysis applications, from core PCR reagents and primers, clean-up solutions, sequencing kits and instrument consumables.
In 2017 NimaGen introduced a novel target enrichment system for routine Next Generation DNA Sequencing, using single molecule Molecular Inversion Probes (smMIPs). The Nimagen EasySeq™ NGS Targeted Capture System offers numerous advantages over existing enrichment systems, with no need for DNA fragmentation, a single amplification step and one-tube purification prior to sequencing, the method is both time and cost effective. Go from sample to data analysis in less than 48 hrs even when working with FFPE derived DNA and avoid the need for additional tests such as qf-PCR or MLPA®
Fabric Genomics™ is a global computational genomics company offering end-to-end genomic data analysis and clinical reporting solutions for clinical labs, hospital labs, country sequencing programs, and life science companies. Fabric Genomics’ analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for panels, exomes, and whole genomes. Our software can process FASTQ or VCF files, providing alignment, variant calling, guideline-driven variant classification, variant annotation, and clinical reporting for hereditary diseases and oncology. Our breakthrough Biograph technology enables accurate detection of structural variants and provides population-scale data mining capabilities. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics and is headquartered in California, with offices in Seattle, Boston and London. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare. Follow us on Twitter, LinkedIn and Facebook.
Transforming genetic data into medical decisions. We are the worldwide leader in the field of early genetic diagnostics for rare hereditary diseases. A database of genetic data from over 110 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. Our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world’s largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.